Biosimilars in Dermatology: Current Situation (Part II)

Area of Science:

• Dermatology
• Pharmacoeconomics
• Biotechnology

Background:

• The Spanish market has seen the introduction of the first biosimilar infliximab, a biologic agent for psoriasis treatment.
• The anticipated arrival of more biosimilars will likely influence dermatologists' prescribing habits and the economic landscape of psoriasis care.

Purpose of the Study:

• To examine the economic repercussions and shifts in dermatological prescribing patterns due to the introduction of biosimilar infliximab.
• To address contentious issues including indication extrapolation, interchangeability, and automatic substitution for biosimilars.
• To review current biosimilars in development for psoriasis and evaluate their potential efficacy, safety, and contribution to healthcare sustainability.

Main Methods:

• Review of market entry data for biosimilar infliximab in Spain.
• Analysis of current literature and clinical development pipelines for psoriasis biosimilars.
• Discussion of regulatory and clinical considerations such as indication extrapolation and interchangeability.

Main Results:

• The first biosimilar infliximab has entered the Spanish market, with further introductions expected.
• Key issues like extrapolation, interchangeability, and substitution require careful consideration.
• Several biosimilars are in development, aiming for comparable efficacy and safety to reference products.

Conclusions:

• The advent of biosimilar infliximab necessitates a re-evaluation of treatment strategies and economic models in psoriasis care.
• Careful assessment of biosimilar data is crucial for ensuring patient safety and therapeutic equivalence.
• Biosimilars hold the potential to enhance the sustainability of public healthcare systems by offering cost-effective treatment options.